Adjuvant therapy for melanoma: nivolumab, pembrolizumab, ipilimumab, dabrafenib and trametinib

• Date : 2021-04-15
• 1    
  0

Neoantigens for melanoma treatment

• Date : 2021-04-15
• 1    
  0

Skin cancer care during the COVID-19 pandemic

• Date : 2021-04-15
• 0    
  0

Combining glycolysis inhibition & CTLA-4 checkpoint blockade

• Date : 2021-04-15
• 0    
  0

Neoadjuvant ipilimumab plus nivolumab in stage III melanoma

• Date : 2021-04-15
• 0    
  0

Alternatives to Mohs surgery for lentigo maligna

• Date : 2021-04-15
• 0    
  0

Surgical procedures used to treat cSCC

• Date : 2021-04-15
• 0    
  0

Assessing CD8+ T-cell infiltration in metastatic melanoma using digital pathology

• Date : 2021-04-15
• 0    
  0

New technologies in the tumor immunology research field

• Date : 2021-04-15
• 0    
  0

Cemiplimab in advanced BCC

• Date : 2021-04-15
• 0    
  0

The current therapeutic landscape for basal cell carcinoma

• Date : 2021-04-15
• 0    
  0

Impact and role of radiotherapy in the management of MCC

• Date : 2021-04-15
• 0    
  0

Triple therapy for melanoma

• Date : 2021-04-17
• 0    
  0

Tumor Profiler: integrating molecular profiling into clinical practice

• Date : 2021-04-17
• 0    
  0

Targeting therapies improve progression-free survival in melanoma

• Date : 2021-04-17
• 0    
  0

Current surgical strategies for metastatic melanoma

• Date : 2021-04-17
• 0    
  0

The future of electrochemotherapy in skin cancer

• Date : 2021-04-17
• 0    
  0

Vismodegib in basal cell carcinoma

• Date : 2021-04-17
• 0    
  0

Neoadjuvant targeted therapy in BRAF V600 mutated melanoma

• Date : 2021-04-17
• 0    
  0

Novel druggable targets for keratinocyte skin cancer

• Date : 2021-04-15
• 0    
  0

CMP-001 for PD-1 refractory patients with melanoma

• Date : 2021-04-15
• 0    
  0

Does radiotherapy elicit an abscopal effect?

• Date : 2021-04-15
• 0    
  0

5-year follow-up: dabrafenib plus trametinib reduces relapse risk in melanoma

• Date : 2021-04-15
• 0    
  0

The current and future treatment of metastatic melanoma

• Date : 2021-04-15
• 0    
  0

Serum NSE levels as a biomarker in MCC

• Date : 2021-04-15
• 0    
  0

Real-world analysis of T-VEC for melanoma

• Date : 2021-04-15
• 0    
  0

Immunotherapies for satellite or ITM melanoma

• Date : 2021-04-15
• 0    
  0

Sentinel node tumor burden for prognostication in melanoma

• Date : 2021-04-15
• 0    
  0

CMP-001 for melanoma and HNSCC

• Date : 2021-04-15
• 0    
  0

Triplet therapies for advanced metastatic melanoma

• Date : 2021-04-15
• 0    
  0

Combining checkpoint blockade therapies in melanoma

• Date : 2021-04-15
• 0    
  0

Neoadjuvant IPI + NIVO in stage III melanoma: updates from OpACIN & OpACIN-neo

• Date : 2021-04-15
• 0    
  0

The future of adjuvant therapy in melanoma

• Date : 2021-04-15
• 0    
  0

The current treatment landscape for MCC

• Date : 2021-04-15
• 0    
  0

Understanding the clinical context for OX40 agonists in melanoma

• Date : 2021-04-15
• 0    
  0

Treating PD-1/PD-L1 refractory MCC

• Date : 2021-04-15
• 0    
  0

Congrès ESMO 2026

• Date : 2026-10-23
• 50    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date : 2025-12-10
• 129    
  0

SABCS 2025 Symposium

• Date : 2025-12-09
• 5324    
  0

Congrès ESMO Asie 2025

• Date : 2025-12-05
• 301    
  0

17ᵉ Congrès Européen Multidisciplinaire sur le Cancer Urologique - EMUC25

• Date : 2025-11-13
• 459    
  0